Coated surfaces, especially those coated with modern low VOC coatings containing 100 g/L VOC or less, such as moldings and panels often become visibly discolored after contact with water repeatedly or over extended periods of time. This problem is enhanced when high polymer content coatings are used on the surfaces. Other issues that can occur with painted surfaces are blistering and surfactant leaching, wherein water soluble components are extracted from the coatings and deposited on the coated surface. Minimizing the amount of water-soluble ingredients has been used to reduce surfactant leaching. However, the water-soluble components are generally substituted with volatile organic compounds (VOCs), resulting in an environmentally undesirable product.
Coating formulations and methods for their preparation are described. The coating formulations can be prepared from aqueous dispersions. The aqueous dispersions include a plurality of multiphase polymer particles and a C8-C18 alkyl alcohol alkoxylated phosphate ester surfactant. The multiphase particles include an acrylic-based copolymer derived from one or more (meth)acrylate monomers and at least one copolymerizable surfactant. In some embodiments, the aqueous dispersion can further include an unreacted portion of the at least one copolymerizable surfactant. Optionally, the acrylic-based copolymer is further derived from one or more acid monomers, one or more amide monomers, and/or one or more molecular weight regulators.
In some embodiments, the acrylic-based copolymer is derived from greater than 0.5% by weight of the at least one copolymerizable surfactant. For example, the acrylic-based copolymer can be derived from greater than 1.0% by weight of the at least one copolymerizable surfactant. In some examples, the at least one copolymerizable surfactant has the following structure of formula I, or a salt thereof:
wherein R1 represents a branched aliphatic hydrocarbon group, a secondary aliphatic hydrocarbon group or a branched aliphatic acyl group, AO and AO′ each independently represents an oxyalkylene group having 2 to 4 carbon atoms, R2 and R3 each independently represents a hydrogen atom or a methyl group, x stands for a number of from 0 to 12, y stands for a number of 0 to 1, z stands for a number of from 1 to 10, X represents a hydrogen atom or an ionic hydrophilic group, m stands for a number of from 0 to 1,000, and n stands for a number of from 0 to 1,000.
In some embodiments, the alkoxylated phosphate ester surfactant is a C12-C15 alkyl alcohol phosphate ester surfactant having from 1 to 70 alkoxylate groups. For example, the alkoxylated phosphate ester surfactant can be a tridecyl alcohol phosphate ester surfactant having from 10 to 40 ethoxylate groups (e.g., greater than 20 to 40). The phosphate ester surfactant is optionally in free acid form.
The acrylic-based copolymer can be derived from greater than 85% by weight of said one or more (meth)acrylate monomers (e.g., from 90% by weight or greater of said one or more (meth)acrylate monomers). In some embodiments, the one or more (meth)acrylate monomers include methyl methacrylate and/or butyl acrylate. In some embodiments, the one or more (meth)acrylate monomers include a crosslinkable (meth)acrylate monomer, such as, for example, acetoacetoxyethyl methacrylate (AAEM). Optionally, the acrylic-based copolymer can be further derived from greater than 0% by weight to 5% by weight of said one or more acid monomers. Examples of the one or more acid monomers include one or more of acrylic acid, methacrylic acid, and itaconic acid.
The acrylic-based copolymer can be derived from greater than 0% by weight to 5% by weight of one or more amide monomers. The one or more amide monomers include, for example, acrylamide and methacrylamide. In some embodiments, the acrylic-based copolymer is derived from greater than 0% by weight to 0.3% by weight of one or more molecular weight regulators that can include tert-dodecyl mercaptan.
In some embodiments, the acrylic-based copolymer is derived from 20-60% by weight methyl methacrylate, 20-60% by weight butyl acrylate, 0-5% by weight acid monomers, 0-5% by weight amide monomers, 0-8% by weight crosslinkable (meth)acrylate monomers, 0-0.3% by weight molecular weight regulators, and greater than 0 to 10% copolymerizable surfactant. For example, the acrylic-based copolymer can be derived from 40-50% by weight methyl methacrylate, 40-55% by weight butyl acrylate, greater than 0 to 5% by weight acid monomers, 0-5% by weight amide monomers, 0-8% by weight crosslinkable (meth)acrylate monomers, 0-0.3% by weight molecular weight regulators, and 1 to 10% copolymerizable surfactant. The acid monomers in the acrylic-based copolymers can include, for example, 0-2.5% by weight acrylic acid and 0-2.5% by weight itaconic acid.
The multiphase particles described herein can have a core phase and a shell phase. In some embodiments, the core phase and the shell phase each comprise greater than 85% of the one or more (meth)acrylate monomers. In some embodiments, the ratio of butyl acrylate to methyl methacrylate in the core phase is 1:1.5 to 5:1 and the ratio of butyl acrylate to methyl methacrylate in the shell phase is 0 to 1:2. The core phase in the multiphase particle can have a Tg of −20 to 30° C. (e.g., −10 to 10° C.) and the shell phase can have a Tg of 60 to 100° C. (e.g., 70 to 90° C.).
Also described herein are coating formulations comprising the aqueous dispersions described herein and one or more fillers. In some embodiments, the coating formulation is a satin or high gloss paint. The one or more fillers can include, for example, one or more of silica, nepheline syenite, calcium carbonate, clay, and titanium dioxide. The coating formulation can have a low volatile organic compound (VOC) content. In some embodiments, the coating formulation comprises less than 100 g/l VOC's (e.g., less than 50 g/l VOC's or less than 10 g/l VOC's).
Further described herein are methods of producing an aqueous dispersion comprising a plurality of multiphase copolymer particles. The methods comprise polymerizing one or more (meth)acrylate monomers, optionally one or more acid monomers, optionally one or more amide monomers, optionally one or more molecular weight regulators, and at least one copolymerizable surfactant, or salt thereof, in an aqueous medium and adding a C8-C18 alkyl alcohol alkoxylated phosphate ester surfactant to the aqueous medium. The polymerizing step can occur in more than one phase.
The details of one or more embodiments are set forth in the description below. Other features, objects, and advantages will be apparent from the description and from the claims.
Coating formulations and methods for their preparation and use are described herein. The coating formulations can be prepared as aqueous dispersions. The aqueous dispersions can include a plurality of multiphase polymer particles and a C8-C18 alkyl alcohol alkoxylated phosphate ester surfactant.
As used herein, the term “multiphase” means that the polymer particles include two or more phases. For example, the polymer particles can include two or more phases, three or more phases, or four or more phases. In some examples, the polymer particles are core/shell polymer particles having a core comprising a first copolymer and a shell formed over the core comprising a second copolymer. The first polymer and the second polymer can include an acrylic-based copolymer. The acrylic-based copolymer is derived from one or more (meth)acrylate monomers, at least one copolymerizable surfactant, and optionally one or more additional monomers.
The acrylic-based copolymers described herein can be derived from greater than 85% by weight of the one or more (meth)acrylate monomers (e.g., from 86% by weight or greater, from 87% by weight or greater, from 88% by weight or greater, from 89% by weight or greater, from 90% by weight or greater, from 91% by weight or greater, from 92% by weight or greater, from 93% by weight or greater, from 94% by weight or greater, from 95% by weight or greater, from 96% by weight or greater, from 97% by weight or greater, from 98% by weight or greater, or from 99% by weight of one or more (meth)acrylate monomers) based on the total weight of monomers. As used herein, the term “(meth)acrylate monomer” includes acrylate, methacrylate, diacrylate, and dimethacrylate monomers. The (meth)acrylate monomers can include esters of α,β-monoethylenically unsaturated mono- and dicarboxylic acids having 3 to 6 carbon atoms with alkanols having 1 to 12 carbon atoms (e.g., esters of acrylic acid, methacrylic acid, maleic acid, fumaric acid, or itaconic acid, with C1-C12, C1-C8, or C1-C4 alkanols). In some embodiments, the copolymer is derived from two or more or three or more (meth)acrylate monomers. Examples of (meth)acrylate monomers suitable for use in the copolymers described herein include butyl acrylate, methyl methacrylate, 2-ethylhexyl acrylate, ethyl acrylate, methyl acrylate, hydroxyethyl(meth)acrylate, hydroxypropyl (meth)acrylate, and methylpolyglycol acrylate. In some embodiments, the copolymer is not derived from polyalkylene glycol methacrylate monomers. The one or more (meth)acrylate monomers can further include a crosslinkable (meth)acrylate monomer. The crosslinkable (meth)acrylate monomers can include, for example, acetoacetoxyethyl methacrylate, acetoacetoxyethyl acrylate, acetoacetoxypropyl methacrylate, acetoacetoxybutyl methacrylate, 2,3-di(acetoacetoxy)propyl methacrylate, 1,4-butanediol diacrylate, ureidoethyl(meth)acrylate, alkylene glycol diacrylates and dimethacrylates (e.g., ethylene glycol diacrylate, 1,3-butylene glycol diacrylate, 1,4-butylene glycol diacrylate and propylene glycol diacrylate), vinyl methacrylate, vinyl acrylate, allyl methacrylate, allyl acrylate, urethane methacrylate, and mixtures of these.
The one or more additional monomers used to prepare the acrylic-based copolymer can optionally include one or more acid monomers. In some examples, the acrylic-based copolymer is derived from greater than 0% by weight to 5% by weight of the one or more acid monomers based on the total weight of the monomers. For example, the acrylic-based copolymer can be derived from greater than 0.5% by weight, greater than 1% by weight, greater than 1.5% by weight, greater than 2% by weight, greater than 2.5% by weight, greater than 3% by weight, greater than 3.5% by weight, greater than 4% by weight, or greater than 4.5% by weight of the one or more acid monomers. Examples of suitable acid monomers for use in the copolymers described herein include α,β-monoethylenically unsaturated mono- and dicarboxylic acids such as acrylic acid, methacrylic acid, itaconic acid, crotonic acid, dimethacrylic acid, ethylacrylic acid, allylacetic acid, vinylacetic acid, maleic acid, fumaric acid, mesaconic acid, methylenemalonic acid, citraconic acid, and mixtures of these. In some embodiments, the acid monomers for use in the copolymers described herein include acrylic acid, methacrylic acid, itaconic acid, and mixtures of these.
The one or more additional monomers can include amide monomers. The amide monomers can be included in the acrylic-based copolymers in an amount of from greater than 0% by weight to 5% by weight based on the total weight of the monomers. For example, the acrylic-based copolymer can be derived from greater than 0.5% by weight, greater than 1% by weight, greater than 1.5% by weight, greater than 2% by weight, greater than 2.5% by weight, greater than 3% by weight, greater than 3.5% by weight, greater than 4% by weight, or greater than 4.5% by weight of the one or more amide monomers. Suitable amide monomers can include acrylamide, alkyl-substituted acrylamide monomers (e.g., methacrylamide, N-tert-butylacrylamide, and N-methyl(meth)acrylamide), N-methylol acrylamide, N-methylol methacrylamide, alkylaminoalkyl(meth)acrylamide, 2-dimethylaminoethyl(meth)acrylamide, 3-dimethylaminopropyl(meth)acrylamide, 3-trimethylammoniumpropyl(meth)acrylamide chloride, diacetonacrylamide, methylenebisacrylamide, and mixtures of these.
Other suitable monomers for use in the acrylic-based copolymers described herein can include conjugated dienes (e.g., 1,3-butadiene or isoprene); α,β-monoethylenically unsaturated mono- and dicarboxylic acid anhydrides (e.g., maleic anhydride, itaconic anhydride, and methylmalonic anhydride); (meth)acrylonitrile; vinyl and vinylidene halides (e.g., vinyl chloride and vinylidene chloride); vinyl esters of C1-C18 mono- or dicarboxylic acids (e.g., vinyl acetate, vinyl propionate, vinyl n-butyrate, vinyl laurate and vinyl stearate); C1-C4 hydroxyalkyl esters of C3-C6 mono- or dicarboxylic acids, especially of acrylic acid, methacrylic acid or maleic acid, or their derivatives alkoxylated with from 2 to 50 mol of ethylene oxide, propylene oxide, butylene oxide or mixtures thereof, or esters of these acids with C1-C18 alcohols alkoxylated with from 2 to 50 mol of ethylene oxide, propylene oxide, butylene oxide or mixtures thereof.
Additional monomers or co-monomers that can be used include linear 1-olefins, branched-chain 1-olefins or cyclic olefins (e.g., ethene, propene, butene, isobutene, pentene, cyclopentene, hexene, and cyclohexene); vinyl and allyl alkyl ethers having 1 to 40 carbon atoms in the alkyl radical, wherein the alkyl radical can possibly carry further substituents such as a hydroxyl group, an amino or dialkylamino group, or one or more alkoxylated groups (e.g., methyl vinyl ether, ethyl vinyl ether, propyl vinyl ether, isobutyl vinyl ether, 2-ethylhexyl vinyl ether, vinyl cyclohexyl ether, vinyl 4-hydroxybutyl ether, decyl vinyl ether, dodecyl vinyl ether, octadecyl vinyl ether, 2-(diethylamino)ethyl vinyl ether, 2-(di-n-butylamino)ethyl vinyl ether, methyldiglycol vinyl ether, and the corresponding allyl ethers); sulfo-functional monomers (e.g., the corresponding alkali metal or ammonium salts of allylsulfonic acid, methallylsulfonic acid, vinylsulfonic acid, allyloxybenzenesulfonic acid, 2-acrylamido-2-methylpropanesulfonic acid; sulfopropyl acrylate; and sulfopropyl methacrylate); dimethyl vinylphosphonate, and other phosphorus monomers; alkylaminoalkyl(meth)acrylates or quaternization products thereof (e.g., 2-(N,N-dimethylamino)ethyl(meth)acrylate, 3-(N,N-dimethylamino)propyl (meth)acrylate, 2-(N,N,N-trimethylammonium)ethyl(meth)acrylate chloride); allyl esters of C1-C30 monocarboxylic acids; N-vinyl compounds (e.g., N-vinylformamide, N-vinyl-N-methylformamide, N-vinylpyrrolidone, N-vinylimidazole, 1-vinyl-2-methylimidazole, 1-vinyl-2-methylimidazoline, N-vinylcaprolactam, vinylcarbazole, 2-vinylpyridine, and 4-vinylpyridine).
The monomers can further include cross-linking monomers, such as hydrazides (e.g., adipic dihydrazide); divinylbenzene; methacrylic acid anhydride; monomers containing 1,3-diketo groups (e.g., diacetone acrylamide); monomers containing urea groups (e.g., acrylamidoglycolic acid and methacrylamidoglycolate methyl ether); and silane crosslinkers (e.g., 3-methacryloxypropyl trimethoxysilane and 3-mercaptopropyl trimethoxysilane). Additional examples of crosslinkers include N-alkylolamides of α,β-monoethylenically unsaturated carboxylic acids having 3 to 10 carbon atoms and esters thereof with alcohols having 1 to 4 carbon atoms (e.g., N-methylolacrylamide and N-methylolmethacrylamide); glyoxal based crosslinkers; monomers containing two vinyl radicals; monomers containing two vinylidene radicals; monomers containing two alkenyl radicals; and monomers containing two non-conjugated ethylenically unsaturated double bonds (e.g., diallyl maleate, diallyl fumarate, and methylenebisacrylamide).
In some embodiments, the acrylic-based copolymer can further include vinyl aromatic monomers (e.g., styrenes). For example, the acrylic-based copolymers can be derived from less than 5% of styrene (e.g., 4% or less, 3% or less, 2% or less, or 1% or less) based on the total weight of the monomers. In some examples, the acrylic-based copolymer is substantially free of vinyl aromatic monomers (e.g., styrenes). For example, the acrylic-based copolymer can be derived from less than 0.9%, less than 0.5%, 0.1%, less than 0.01%, or 0% vinyl aromatic monomers based on the total weight of the monomers.
In some examples, the acrylic-based copolymer is derived from less than 15% by weight of one or more of acrylonitrile, methacrylonitrile, vinylbenzonitrile, cyanoacrylates, vinyl chloride, vinylidene chloride, and cyano-styrenes. For example, the acrylic-based copolymer can be derived from less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of these monomers. In some examples, the acrylic-based copolymer is substantially free from these monomers.
As described above, the acrylic-based copolymer is also derived from at least one copolymerizable surfactant. In some embodiments, the acrylic-based copolymer is derived from greater than 0.5% by weight of the at least one copolymerizable surfactant. For example, the at least one copolymerizable surfactant can be included in an amount from greater than 1% by weight, greater than 1.5% by weight, greater than 2% by weight, greater than 2.5% by weight, greater than 3% by weight, greater than 3.5% by weight, greater than 4% by weight, or greater than 4.5% by weight based on the total weight of the monomers. In some embodiments, the total amount of copolymerizable surfactant added to the copolymer does not react in the polymerization reaction. For example, 5% or less (e.g., 4% or less, 3% or less, 2% or less, 1% or less, or 0.5% or less) of the added copolymerizable sulfate surfactant can remain unreacted.
In some examples, the at least one copolymerizable surfactant can have a structure represented by Formula I or a salt thereof.
In Formula I, R1 represents a branched aliphatic hydrocarbon group, a secondary aliphatic hydrocarbon group, or a branched aliphatic acyl group. Also in Formula I, AO and AO′ each independently represents an oxyalkylene group having 2 to 4 carbon atoms. Additionally in Formula I, R2 and R3 each independently represents a hydrogen atom or a methyl group. Further in Formula I, x stands for a number of from 0 to 12, y stands for a number of 0 to 1, z stands for a number of from 1 to 10, m stands for a number of from 0 to 1,000, and n stands for a number of from 0 to 1,000. Also in Formula I, X represents a hydrogen atom or an ionic hydrophilic group.
In some embodiments, the copolymerizable surfactant can have the following structure represented by Structure I-A:
In Structure I-A, R1 is C9-C15 alkyl or C7-C11 alkyl-phenyl, X is H, SO3NH4, and/or SO3Na, and m is 3 to 50. In some embodiments, R1 is C10-C14 alkyl, X is H and/or SO3NH4, and m is 5 to 40. In some embodiments, m is 5 to 25, 5 to 20, or 5 to 15 (e.g., m=10). Exemplary copolymerizable surfactants wherein R1 is C10-C14 alkyl can include ADEKA REASOAP series ER and SR surfactants (Adeka Corporation; Tokyo, Japan), such as ER-10, ER-20, ER-30, ER-40, SR-10, SR-20, and SR-1025. For example, ADEKA REASOAP SR-10, which includes ammonium salts of poly(oxy-1,2-ethanediyl), alpha-sulfo-omega-[1-(hydroxymethyl)-2-(2-propenyloxy)ethoxy]-, C11-rich, C10-14-branched alkyl ethers, can be used. Exemplary copolymerizable surfactants in which R1 is C7-C11 alkyl-phenyl can include ADEKA REASOAP series NE and SE surfactants, such as NE-10, NE-20, NE-30, NE-40, NE-50, SE-10N, SE-20N, and SE-1025N.
Further examples of suitable copolymerizable surfactants include MAXEMUL surfactants, alkenyl functional non-ionic surfactants commercially available from Croda Coatings & Polymers (Edison, N.J.) and HITENSOL BC surfactants, a series of polyoxyethylene alkylphenyl ether ammonium sulfates commercially available from Dai-Ichi Kogyo Seiyaku Co., Ltd. (Kyoto, Japan). Additional examples of suitable copolymerizable surfactants are described in U.S. Pat. No. 6,841,655, which is hereby incorporated by reference in its entirety.
In addition to the monomers and copolymerizable surfactants, small amounts (e.g., from greater than 0% by weight to 0.3% by weight) of molecular weight regulators, such as tert-dodecyl mercaptan, can be used. Such regulators can be added to the polymerization zone in a mixture with the monomers to be polymerized and are considered part of the total amount of monomers used in the copolymer.
In some embodiments, the acrylic-based copolymer can be derived from 20-60% by weight methyl methacrylate, 20-60% by weight butyl acrylate, 0-5% by weight acid monomers, 0-5% by weight amide monomers, 0-8% by weight crosslinkable (meth)acrylate monomers, 0-0.3% by weight molecular weight regulators, and greater than 0 to 10% copolymerizable surfactant. In some embodiments, the acrylic-based copolymer can be derived from monomers consisting essentially of 20-60% by weight methyl methacrylate, 20-60% by weight butyl acrylate, 0-5% by weight acid monomers, 0-5% by weight amide monomers, 0-8% by weight crosslinkable (meth)acrylate monomers, 0-0.3% by weight molecular weight regulators, and greater than 0 to 10% copolymerizable surfactant. In some embodiments, the acrylic-based copolymer can be derived from 40-50% by weight methyl methacrylate, 40-55% by weight butyl acrylate, greater than 0 to 5% by weight acid monomers, 0-5% by weight amide monomers, 0-8% by weight crosslinkable (meth)acrylate monomers, 0-0.3% by weight molecular weight regulators, and 1 to 10% copolymerizable surfactant. The acid monomers can include, for example, 0-2.5% by weight acrylic acid and 0-2.5% by weight itaconic acid.
The acrylic-based copolymers can be prepared by polymerizing the monomers using free-radical emulsion polymerization. The emulsion polymerization temperature is generally from 30° C. to 95° C. or from 75° C. to 90° C. The polymerization medium can include water alone or a mixture of water and water-miscible liquids, such as methanol. In some embodiments, water is used alone. The emulsion polymerization can be carried out either as a batch, semi-batch, or continuous process. Typically, a semi-batch process is used. In some embodiments, a portion of the monomers can be heated to the polymerization temperature and partially polymerized, and the remainder of the polymerization batch can be subsequently fed to the polymerization zone continuously, in steps or with superposition of a concentration gradient. In some embodiments, the copolymerizable surfactant to be used can be provided initially in the polymerization zone in dissolved form in an aqueous mixture.
The free-radical emulsion polymerization can be carried out in the presence of a free-radical polymerization initiator. The free-radical polymerization initiators that can be used in the process are all those which are capable of initiating a free-radical aqueous emulsion polymerization including alkali metal peroxydisulfates and H2O2, or azo compounds. Combined systems can also be used comprising at least one organic reducing agent and at least one peroxide and/or hydroperoxide, e.g., tert-butyl hydroperoxide and the sodium metal salt of hydroxymethanesulfinic acid or hydrogen peroxide and ascorbic acid. Combined systems can also be used additionally containing a small amount of a metal compound which is soluble in the polymerization medium and whose metallic component can exist in more than one oxidation state, e.g., ascorbic acid/iron(II) sulfate/hydrogen peroxide, where ascorbic acid can be replaced by the sodium metal salt of hydroxymethanesulfinic acid, sodium sulfite, sodium hydrogen sulfite or sodium metal bisulfite and hydrogen peroxide can be replaced by tert-butyl hydroperoxide or alkali metal peroxydisulfates and/or ammonium peroxydisulfates. In the combined systems, the carbohydrate derived compound can also be used as the reducing component. In general, the amount of free-radical initiator systems employed can be from 0.1 to 2%, based on the total amount of the monomers to be polymerized. In some embodiments, the initiators are ammonium and/or alkali metal peroxydisulfates (e.g., sodium peroxydisulfates), alone or as a constituent of combined systems. The manner in which the free-radical initiator system is added to the polymerization reactor during the free-radical aqueous emulsion polymerization is not critical. It can either all be introduced into the polymerization reactor at the beginning, or added continuously or stepwise as it is consumed during the free-radical aqueous emulsion polymerization. In detail, this depends in a manner known to an average person skilled in the art both from the chemical nature of the initiator system and on the polymerization temperature. In some embodiments, some is introduced at the beginning and the remainder is added to the polymerization zone as it is consumed. It is also possible to carry out the free-radical aqueous emulsion polymerization under superatmospheric or reduced pressure.
Groups of monomers can be added to the polymerization reaction in two phases to form a multiphase particle with a core phase and a shell phase. The ratios and amounts of monomers present in each phase can vary. For example, the ratio of butyl acrylate to methyl methacrylate in the core phase can be 1:1.5 to 5:1 while the ratio of butyl acrylate to methyl methacrylate in the shell phase can be 0 to 1:2. In some embodiments, the core phase can be prepared by including in the reactor 1.0-5.0 parts by weight of the copolymerizable surfactant (e.g. ADEKA REASOAP SR-1025), 0.5-2.0 parts by weight of the phosphate ester surfactant (e.g. DEXTROL OC-40 or MAPHOS 36P), 10-30 parts by weight methyl methacrylate, 20-50 parts by weight butyl acrylate, 0-5.0 parts by weight of an acid monomer (e.g. itaconic acid) and 0-8.0 parts by weight of a copolymerizable acrylate monomer (e.g. AAEM), and the shell phase can be prepared by then including in the reactor 0-5.0 parts by weight of the copolymerizable surfactant (e.g. ADEKA REASOAP SR-1025), 10-25 parts by weight methyl methacrylate, 0-5 parts by weight butyl acrylate, 0-5.0 parts by weight of an acid monomer (e.g. acrylic acid) and 0-8.0 parts by weight of a copolymerizable acrylate monomer (e.g. AAEM), and 0-0.3 parts by weight of a molecular weight regulator (e.g. tert-dodecyl mercaptan).
In some examples, the amount of (meth)acrylate monomers in each of the core phase and the shell phase is greater than 85% based on the weight of the monomers. For example, the amount of (meth)acrylate monomers in the core phase and/or the shell phase can be 86% by weight or greater, 87% by weight or greater, 88% by weight or greater, 89% by weight or greater, 90% by weight or greater, 91% by weight or greater, 92% by weight or greater, 93% by weight or greater, 94% by weight or greater, 95% by weight or greater, 96% by weight or greater, 97% by weight or greater, 98% by weight or greater, or 99% by weight of one or more (meth)acrylate monomers, based on the total weight of monomers.
As described above, the core phase can include a first polymer and the shell phase can include a second polymer. In some examples, the polymer in the core phase can have a Tg of from −10 to 10° C. For example, the core phase can have a Tg of greater than −10° C., greater than −9° C., greater than −8° C., greater than −7° C., greater than −6° C., greater than −5° C., greater than −4° C., greater than −3° C., greater than −2° C., or greater than −1° C. (e.g., 0° C.). The core phase can also have a Tg of less than 10° C., less than 9° C., less than 8° C., less than 7° C., less than 6° C., less than 5° C., less than 4° C., less than 3° C., less than 2° C., or less than 1° C. In some examples, the polymer in the shell phase can have a Tg of from 60 to 100° C. For example, the shell phase can have a Tg of greater than 60° C., greater than 65° C., greater than 70° C., or greater than 75° C. (e.g., 80° C.). The shell phase can also have a Tg of less than 100° C., less than 95° C., less than 90° C., or less than 85° C. Alternatively, the core phase can have a Tg of from 60 to 100° C. and the shell phase can have a Tg of from −10 to 10° C. The multiphase polymer particles can have a median particle size of from 80 nm to 130 nm (e.g., from 90 nm to 120 nm or from 95 nm to 110 nm).
The multiphase polymer particles described herein can be combined with water to form an aqueous dispersion. In addition to the plurality of multiphase polymer particles, the aqueous dispersion further includes a C8-C18 alkyl alcohol alkoxylated phosphate ester surfactant. The amount of alkoxylated phosphate ester surfactant can range from 0.1% to 3% by weight (e.g., from 0.5 to 2% by weight) based on the solids of the dispersion. In some examples, the alkoxylated phosphate ester surfactant is a C12-C15 alkyl alcohol phosphate ester surfactant (e.g. a tridecyl alcohol phosphate ester surfactant). In some examples, the alkoxylated phosphate ester surfactant has from 1 to 60 alkoxylate groups or from 20 to 40 ethoxylate groups. The phosphate ester surfactant can be in free acid form or in salt form. Examples of suitable commercially available alkoxylated phosphate ester surfactant include DEXTROL OC-40, a free-acid form of a tridecyl alcohol ethoxylated phosphate ester available from Ashland Inc. (Covington, Ky.) and MAPHOS 36P, a tridecyl alcohol ethoxylated phosphate ester available from BASF Corporation (Florham Park, N.J.).
As described above, a percentage of the copolymerizable surfactant can remain unreacted. In these examples, the aqueous dispersion further includes the unreacted portion of the at least one copolymerizable surfactant.
In some embodiments, the aqueous dispersion is substantially free from non-polymerizable sodium sulfate surfactants. For example, the aqueous dispersions can include from less than 0.01% or 0% of non-polymerizable sodium sulfate surfactants based on the dry weight of the dispersions.
The aqueous dispersion can be used to prepare products, including coatings, adhesives, and caulks. For example, the aqueous dispersions described herein can be combined with one or more pigments in the coating composition. The term “pigment” as used herein includes non-film-forming solids such as extenders and fillers. The at least one pigment is preferably selected from the group consisting of TiO2 (in both anastase and rutile forms), clay (aluminum silicate), CaCO3 (in both ground and precipitated forms), aluminum oxide, silicon dioxide, magnesium oxide, talc (magnesium silicate), barytes (barium sulfate), zinc oxide, zinc sulfite, sodium oxide, potassium oxide and mixtures thereof. Suitable mixtures include blends of metal oxides such as those sold under the marks Minex® (oxides of silicon, aluminum, sodium and potassium commercially available from Unimin Specialty Minerals), Celites® (aluminum oxide and silicon dioxide commercially available from Celite Company), Atomites® (commercially available from English China Clay International), and Attagels® (commercially available from BASF Corporation). More preferably, the at least one pigment includes TiO2, CaCO3, or clay. Generally, the mean particle sizes of the pigments range from about 0.01 to about 50 microns. For example, the TiO2 particles used in the aqueous coating composition typically have a mean particle size of from about 0.15 to about 0.40 microns. The pigment can be added to the aqueous coating composition as a powder or in slurry form. The pigment is preferably present in the aqueous coating composition in an amount from about 5 to about 50 percent by weight, more preferably from about 10 to about 40 percent by weight (i.e. the weight percentage of the pigment based on the total weight of the coating composition).
The coating composition can optionally contain conventional coating additives such as, for example, dispersants, additional surfactants (i.e. wetting agents), rheology modifiers, defoamers, thickeners, initiators (including photoinitiators), stabilizers, buffering agents, salts, preservatives, fire retardants, biocides, mildewcides, protective colloids, corrosion inhibitors, crosslinkers, crosslinking promoters, lubricants, colorants such as colored pigments and dyes, waxes, perfumes, co-solvents, and the like.
The optional additives may be used in a manner and amount as known in the art of conventional latex compositions, but the additives preferably do not increase the total VOC content of the composition above the preferred values provided herein. Thus, although the compositions can include anti-freeze agents and coalescing agents in an amount of 3% or less, 2% or less, 1% or less, or 0.5% or less, in some embodiments, the coating formulations are substantially free of anti-freeze agents and coalescing agents (e.g., include 0% of anti-freeze agents and coalescing agents). The coating formulations can have a VOC content of less than 100 g/l, less than 50 g/l, less than 10 g/l, less than 5 g/l, or less than 1 g/l, as determined according to ASTM Method D3960. In some examples, the coating formulations are substantially free of VOCs. In these embodiments, the coating formulations can be derived from less than 0.9%, less than 0.5%, 0.1%, less than 0.01%, or 0% of VOCs based on the total weight of the monomers.
The coating formulations described herein can be used to prepare clear and pigmented systems. In some examples, the coating formulations are used to produce flat, satin, or high gloss paint. The gloss of the coating formulations can be determined using a gloss meter (e.g., BYK Gardner Trigloss 4520; Bavaria, Germany) according to the ASTM Test Method for Specular Gloss (D523). Alternatively, the gloss of the coating formulation can be determined using goniophotometry. In some examples, suitable gloss numbers for flat paint at 85° can be, for example, from 0 to 7. Suitable gloss numbers for semi-gloss paint at 20° can range from 10 to 25. When measured at 60°, suitable gloss numbers for semi-gloss paint can range from 40 to 65. For high gloss paints, suitable gloss numbers can range from 40 to 60 when measured at 20° and from 70 to greater than 90 when measured at 60°. The coating formulations described herein also display water whitening resistance and low surfactant leaching properties.
The examples below are intended to further illustrate certain aspects of the methods and compositions described herein, and are not intended to limit the scope of the claims.
An aqueous dispersion of multiphase polymer particles is prepared by combining multiphase particles including an acrylic-based copolymer with an alkoxylated phosphate ester surfactant. Exemplary ingredients used to prepare the acrylic-based copolymer for use in the multiphase polymer particles described herein are shown in Table 1.
The monomers (methyl methacrylate, butyl acrylate, itaconic acid, acrylic acid, and acetoacetoxyethyl methacrylate) and the copolymerizable sulfate surfactant are copolymerized in the presence of tert-dodecyl mercaptan to form multiphase polymer particles. Approximately 0.5 to 2% of the copolymerizable sulfate surfactant can remain unreacted.
An aqueous dispersion comprising multiphase polymer particles was prepared by copolymerizing monomers and the copolymerizable sulfate surfactant in the presence of tert-dodecyl mercaptan and a phosphate ester surfactant. The ingredients were copolymerized in two phases. The composition of each phase is shown in Table 2.
ADEKA REASOAP SR-1025 (Adeka Corporation; Tokyo, Japan) was used as the copolymerizable sulfate surfactant to prepare the multiphase polymer particles. DEXTROL OC-40 (Ashland Inc.; Covington, Ky.) was used as the phosphate ester surfactant. The Tg of phase 1 was 0° C. and the Tg of phase 2 was 80° C. The particle sizes of the resulting multi-phase particles ranged from 80 to 130 nm.
The aqueous dispersion from Example 2 was prepared as a deep base coating formulation tinted with colored pigments at the rate of 12 oz pigment dispersion to 116 oz of paint and was applied at 250 microns to a black Leneta scrub panel P121-10N (The Leneta Company; Mahwah, N.J.). The panel was dried for 24 hours and a drop of water was then placed on the panel. After a few minutes, the panel was tilted and the water was allowed to run down the panel. The water whitening on the panel was determined, according to the ASTM D7190-10 method, based on the degree of color change on the tested portion of the panel two minutes after application and drying. The degree of color change was measured on a scale from 0 to 10, where 10 represented no water whitening. Additional tested parameters included the hydrophobicity of the surface as determined by how much the drop spread over the surface, the whiteness of the water trail upon tilting the panel, the rate at which the water spots dry, and the overall surfactant leaching or streaking left by the water trail. The coating formulation displayed minimal water whitening to the panel.
The surfactant leaching test generally based on ASTM 7190 was performed approximately 24 hours after the water whitening test as described in Example 3. The panel was examined for “snail trails” left on the panel after the water dried. The coating formulation displayed no surfactant leaching.
The dispersions, formulations, and methods of the appended claims are not limited in scope by the specific dispersions, formulations, and methods described herein, which are intended as illustrations of a few aspects of the claims and any dispersions, formulations, and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the dispersions, formulations, and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative dispersion materials and method steps disclosed herein are specifically described, other combinations of the dispersion materials and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein; however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments and are also disclosed.
This application claims priority to U.S. Provisional Application No. 61/447,398, filed Feb. 28, 2011, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3607486 | Jacks et al. | Sep 1971 | A |
4011388 | Murphy et al. | Mar 1977 | A |
4230810 | Lattime | Oct 1980 | A |
4477623 | Pons et al. | Oct 1984 | A |
4611087 | Yamashita et al. | Sep 1986 | A |
4612343 | Okuzono et al. | Sep 1986 | A |
4686254 | Lochhead et al. | Aug 1987 | A |
4814514 | Yokota et al. | Mar 1989 | A |
4900615 | Kissell et al. | Feb 1990 | A |
4939283 | Yokota et al. | Jul 1990 | A |
4943612 | Morita et al. | Jul 1990 | A |
4952650 | Young et al. | Aug 1990 | A |
4966791 | Kissell et al. | Oct 1990 | A |
4987695 | Preiser | Jan 1991 | A |
5084505 | Biale | Jan 1992 | A |
5094998 | Hoshino et al. | Mar 1992 | A |
5133898 | Fock et al. | Jul 1992 | A |
5168087 | Li Bassi et al. | Dec 1992 | A |
5173534 | Biale | Dec 1992 | A |
5207954 | Lewis et al. | May 1993 | A |
5268437 | Holy et al. | Dec 1993 | A |
5273676 | Boeckh et al. | Dec 1993 | A |
5275650 | Mongoin et al. | Jan 1994 | A |
5308890 | Snyder | May 1994 | A |
5326814 | Biale | Jul 1994 | A |
5332854 | Yokota et al. | Jul 1994 | A |
5338485 | Fock et al. | Aug 1994 | A |
5340870 | Clinnin et al. | Aug 1994 | A |
5348998 | Ito et al. | Sep 1994 | A |
5380784 | Usuki et al. | Jan 1995 | A |
5389722 | Nagasuna et al. | Feb 1995 | A |
5391624 | Rasoul et al. | Feb 1995 | A |
5414041 | Larson et al. | May 1995 | A |
5498659 | Esser | Mar 1996 | A |
5506325 | Swarup et al. | Apr 1996 | A |
5534577 | Namba et al. | Jul 1996 | A |
5637142 | Kubo et al. | Jun 1997 | A |
5661206 | Tanaka et al. | Aug 1997 | A |
5679735 | Geissler et al. | Oct 1997 | A |
5679835 | Inden et al. | Oct 1997 | A |
5686523 | Chen et al. | Nov 1997 | A |
5707445 | Yamato et al. | Jan 1998 | A |
5721330 | Ma | Feb 1998 | A |
5726268 | Sakamoto | Mar 1998 | A |
5859112 | Overbeek et al. | Jan 1999 | A |
5895801 | Lee | Apr 1999 | A |
5911820 | Satoh et al. | Jun 1999 | A |
5925184 | Hirata et al. | Jul 1999 | A |
5928783 | Phan et al. | Jul 1999 | A |
5962571 | Overbeek et al. | Oct 1999 | A |
5969037 | Hatano et al. | Oct 1999 | A |
5977242 | Origuchi et al. | Nov 1999 | A |
5998543 | Collins et al. | Dec 1999 | A |
6005042 | Desor et al. | Dec 1999 | A |
6028155 | Collins et al. | Feb 2000 | A |
6048953 | Kawashima et al. | Apr 2000 | A |
6087418 | Yamashita et al. | Jul 2000 | A |
6103788 | Harui et al. | Aug 2000 | A |
6140435 | Zanotti-Russo | Oct 2000 | A |
6147165 | Lee et al. | Nov 2000 | A |
6156860 | Tanaka et al. | Dec 2000 | A |
6166112 | Hirata et al. | Dec 2000 | A |
6174980 | Hirata et al. | Jan 2001 | B1 |
6187841 | Tanaka et al. | Feb 2001 | B1 |
6201089 | Carter | Mar 2001 | B1 |
6214467 | Edwards et al. | Apr 2001 | B1 |
6214958 | Le-Khac et al. | Apr 2001 | B1 |
6225389 | Saint Victor | May 2001 | B1 |
6239241 | Yamato et al. | May 2001 | B1 |
6258162 | Kawakami et al. | Jul 2001 | B1 |
6262144 | Zhao et al. | Jul 2001 | B1 |
6264739 | Yamato et al. | Jul 2001 | B1 |
6265495 | Hirata et al. | Jul 2001 | B1 |
6271326 | Nishikawa et al. | Aug 2001 | B1 |
6294015 | Yamashita et al. | Sep 2001 | B1 |
6297328 | Collins et al. | Oct 2001 | B1 |
6313244 | Tanaka et al. | Nov 2001 | B1 |
6326446 | Carter | Dec 2001 | B2 |
6329461 | Akiyama et al. | Dec 2001 | B1 |
6376581 | Tanaka et al. | Apr 2002 | B1 |
6384168 | Tanaka et al. | May 2002 | B1 |
6388038 | Hirata et al. | May 2002 | B1 |
6417269 | Murray et al. | Jul 2002 | B1 |
6462110 | Satoh et al. | Oct 2002 | B2 |
6471885 | Chiang et al. | Oct 2002 | B2 |
6476108 | Mogi et al. | Nov 2002 | B1 |
6489387 | Mallya et al. | Dec 2002 | B2 |
6489396 | Nakamura et al. | Dec 2002 | B2 |
6506837 | Destarac et al. | Jan 2003 | B2 |
6524679 | Hauber et al. | Feb 2003 | B2 |
6527850 | Schwartz et al. | Mar 2003 | B2 |
6534590 | Aso et al. | Mar 2003 | B1 |
6534597 | Adam et al. | Mar 2003 | B2 |
6538047 | Miyabayashi | Mar 2003 | B1 |
6545083 | Hirata et al. | Apr 2003 | B1 |
6555641 | Parker et al. | Apr 2003 | B2 |
6569234 | Yamashita et al. | May 2003 | B2 |
6569949 | Lee et al. | May 2003 | B1 |
6569976 | Baxter et al. | May 2003 | B2 |
6576051 | Bardman et al. | Jun 2003 | B2 |
6593412 | Rabasco et al. | Jul 2003 | B1 |
6602949 | Furukawa et al. | Aug 2003 | B2 |
6605662 | Zhao et al. | Aug 2003 | B2 |
6620890 | Yamashita et al. | Sep 2003 | B1 |
6624243 | Stark et al. | Sep 2003 | B2 |
6638998 | Zhao et al. | Oct 2003 | B2 |
6652867 | Vincent et al. | Nov 2003 | B1 |
6656266 | Barlet-Gouedard et al. | Dec 2003 | B1 |
6673885 | Shibata et al. | Jan 2004 | B1 |
6683145 | Grandhee | Jan 2004 | B2 |
6699931 | Kuo et al. | Mar 2004 | B2 |
6713553 | Gonnon et al. | Mar 2004 | B2 |
6716943 | Tanaka et al. | Apr 2004 | B2 |
6723786 | Husemann et al. | Apr 2004 | B2 |
6723813 | Asai et al. | Apr 2004 | B2 |
6727315 | Yamamoto et al. | Apr 2004 | B2 |
6737493 | Mochizuki et al. | May 2004 | B2 |
6743834 | Yokoyama et al. | Jun 2004 | B2 |
6759463 | Lorah et al. | Jul 2004 | B2 |
6770354 | Randall et al. | Aug 2004 | B2 |
6780924 | Shih et al. | Aug 2004 | B2 |
6815513 | Le-Khac et al. | Nov 2004 | B2 |
6841655 | Gota et al. | Jan 2005 | B1 |
6869988 | Schwartz et al. | Mar 2005 | B2 |
6878321 | Hauber et al. | Apr 2005 | B2 |
6900275 | Tomita et al. | May 2005 | B2 |
6905814 | Aubay et al. | Jun 2005 | B1 |
6919388 | Nishikawa et al. | Jul 2005 | B2 |
6921801 | Collette et al. | Jul 2005 | B2 |
6933415 | Zhao et al. | Aug 2005 | B2 |
6946505 | Yuasa et al. | Sep 2005 | B2 |
6956082 | Johnson et al. | Oct 2005 | B1 |
6960624 | Gonnon et al. | Nov 2005 | B2 |
6964991 | Chen et al. | Nov 2005 | B2 |
6969734 | Pressley et al. | Nov 2005 | B1 |
7008977 | Sakai et al. | Mar 2006 | B2 |
7098250 | Sawada et al. | Aug 2006 | B2 |
7105593 | Solomon et al. | Sep 2006 | B2 |
7115682 | Guo et al. | Oct 2006 | B2 |
7144944 | Murase et al. | Dec 2006 | B2 |
7217443 | Bobsein et al. | May 2007 | B2 |
7265165 | Ohkubo et al. | Sep 2007 | B2 |
7285590 | Holub et al. | Oct 2007 | B2 |
7297328 | Löffler et al. | Nov 2007 | B2 |
7339002 | Guo et al. | Mar 2008 | B2 |
7378479 | Tamareselvy et al. | May 2008 | B2 |
7393888 | Yoshimura | Jul 2008 | B2 |
7445849 | Apitz et al. | Nov 2008 | B2 |
7612126 | Roschmann et al. | Nov 2009 | B2 |
7705081 | Porzio et al. | Apr 2010 | B2 |
7705082 | Porzio et al. | Apr 2010 | B2 |
7776975 | Blankenship et al. | Aug 2010 | B2 |
7893131 | Matthews et al. | Feb 2011 | B2 |
7989545 | Farwaha et al. | Aug 2011 | B2 |
20020065208 | Aubay et al. | May 2002 | A1 |
20020103316 | Tanaka et al. | Aug 2002 | A1 |
20020123588 | Adam et al. | Sep 2002 | A1 |
20020157573 | Pellett | Oct 2002 | A1 |
20020168533 | Taylor et al. | Nov 2002 | A1 |
20030031719 | Kipp et al. | Feb 2003 | A1 |
20030134973 | Chen et al. | Jul 2003 | A1 |
20030162890 | Kalantar et al. | Aug 2003 | A1 |
20030212195 | Matsumoto et al. | Nov 2003 | A1 |
20040048963 | Sawada et al. | Mar 2004 | A1 |
20040052746 | Tamareselvy et al. | Mar 2004 | A1 |
20040054111 | Kalantar et al. | Mar 2004 | A1 |
20040075074 | Kubota et al. | Apr 2004 | A1 |
20040109836 | Löffler et al. | Jun 2004 | A1 |
20040127607 | Schober et al. | Jul 2004 | A1 |
20040152379 | McLarty, III et al. | Aug 2004 | A1 |
20040170873 | Smith | Sep 2004 | A1 |
20040185231 | Dimmick | Sep 2004 | A1 |
20040209074 | Randall et al. | Oct 2004 | A1 |
20040221395 | Biver et al. | Nov 2004 | A1 |
20040235687 | Shiba et al. | Nov 2004 | A1 |
20040242760 | Shibai et al. | Dec 2004 | A1 |
20050075416 | Miyabayashi | Apr 2005 | A1 |
20050131176 | Zhao | Jun 2005 | A1 |
20050202742 | Smith et al. | Sep 2005 | A1 |
20050202997 | Hanazawa et al. | Sep 2005 | A1 |
20050222301 | Yuasa et al. | Oct 2005 | A1 |
20050229519 | Colbert et al. | Oct 2005 | A1 |
20050250887 | Yang et al. | Nov 2005 | A1 |
20050256257 | Betremieux et al. | Nov 2005 | A1 |
20050266225 | Currier et al. | Dec 2005 | A1 |
20050266238 | Amano et al. | Dec 2005 | A1 |
20060024494 | Amano et al. | Feb 2006 | A1 |
20060035112 | Veeramasuneni et al. | Feb 2006 | A1 |
20060057371 | Kobayashi et al. | Mar 2006 | A1 |
20060063868 | Janmaat et al. | Mar 2006 | A1 |
20060115669 | Shinohara et al. | Jun 2006 | A1 |
20060135684 | Killilea et al. | Jun 2006 | A1 |
20060135686 | Killilea et al. | Jun 2006 | A1 |
20060178494 | Pabon et al. | Aug 2006 | A1 |
20060188714 | Tetsumoto et al. | Aug 2006 | A1 |
20060205865 | Kim et al. | Sep 2006 | A1 |
20060235131 | Hughes et al. | Oct 2006 | A1 |
20060240236 | Bland et al. | Oct 2006 | A1 |
20060277854 | Egan | Dec 2006 | A1 |
20060278267 | Miyazawa | Dec 2006 | A1 |
20070012221 | Maeta et al. | Jan 2007 | A1 |
20070105982 | Roschmann et al. | May 2007 | A1 |
20070123637 | Pernecker et al. | May 2007 | A1 |
20070135559 | Fukumon et al. | Jun 2007 | A1 |
20070190172 | Bobbert | Aug 2007 | A1 |
20070287019 | Chen et al. | Dec 2007 | A1 |
20070299180 | Joecken | Dec 2007 | A1 |
20080057346 | Peuramaki | Mar 2008 | A1 |
20080069793 | Löffler et al. | Mar 2008 | A1 |
20080139737 | Alderfer et al. | Jun 2008 | A1 |
20080245012 | Boisvert et al. | Oct 2008 | A1 |
20080245259 | Chowdhry et al. | Oct 2008 | A1 |
20090043035 | Cabrera | Feb 2009 | A1 |
20090143528 | Mestach et al. | Jun 2009 | A1 |
20090163619 | Hsu et al. | Jun 2009 | A1 |
20090171005 | Finegan et al. | Jul 2009 | A1 |
20090326135 | Nair et al. | Dec 2009 | A1 |
20100062264 | Hayes et al. | Mar 2010 | A1 |
20100113646 | Bardman et al. | May 2010 | A1 |
Number | Date | Country |
---|---|---|
2180989 | Jun 2003 | CA |
3811102 | Oct 1988 | DE |
422120 | Apr 1991 | EP |
0725044 | Jul 1996 | EP |
1369434 | Dec 2003 | EP |
1712573 | Oct 2006 | EP |
1798258 | Jun 2007 | EP |
1911808 | Apr 2008 | EP |
1242290 | Aug 1971 | GB |
2264114 | Aug 1993 | GB |
2319522 | May 1998 | GB |
59203742 | Nov 1984 | JP |
08217505 | Aug 1996 | JP |
11209560 | Aug 1999 | JP |
03218956 | Aug 2001 | JP |
2002145969 | May 2002 | JP |
2004210919 | Jul 2004 | JP |
2004217782 | Aug 2004 | JP |
2009256481 | Nov 2009 | JP |
8912618 | Dec 1989 | WO |
9711996 | Apr 1997 | WO |
9828240 | Jul 1998 | WO |
0022016 | Apr 2000 | WO |
0063294 | Oct 2000 | WO |
0212144 | Feb 2002 | WO |
2004020477 | Mar 2004 | WO |
2005095532 | Oct 2005 | WO |
2009095569 | Aug 2009 | WO |
2010026065 | Mar 2010 | WO |
Entry |
---|
Dectrol OC-70 Phosphate Ester Surfactant Product Data Sheet (2011). |
ADEKA REASOAP Material Safety Data Sheet, ADEKA Corp., revised Sep. 10, 2006, 7 pages. |
ADEKA, “New Reactive Surfactant: Adeka reasoap ER/SR Series,” Asahi Denka Co., Ltd. Jan. 29, 2003, 4 pp. |
Mayer, H., “Masonry Protection with Silanes, Siloxanes and Silicone Resins,” Surface Coatings International, JOCCA, vol. 81, No. 2, Feb. 1998, pp. 89-93. |
Mizutani, Tsutomu, et al., “Preparation of Spherical Nanocomposites Consisting of Silica Core and Polyacrylate Shell by Emulsion Polymerization,” Journal of Applied Polymer Science, vol. 99, 2006, pp. 659-669. |
NeoCAR® Acrylics 7657 and 7658, NeoCAR® Acrylics: The Next Step in Technology and Performance, Union Carbide, 1998, 16 pages. |
Product Bulletin Vv 1.2, VeoVa™ Monomers Applications and Advantages, Hexion Specialty Chemicals, 2007, 4 pages. |
Product Data Sheet, VeoVa™ Monomer 10, Resolution Performance Products, Reissued issued Oct. 2002, 3 pages. |
VeoVa™ Vinyl Esters, Hexion Specialty Chemicals, retrieved from http://www.hexion.com/Products/ProductLiterature.aspx?id=693 on May 26, 2008, 1 page. |
Willenbacher, N., et al., “New Laboratory Test to Characterize Immobilization and Dewatering of Paper Coating Colors,” TAPPI Journal, vol. 82, No. 8, 1999, pp. 167-174. |
International Preliminary Report on Patentability and Written Opinion, dated Mar. 8, 2011, in related International Application No. PCT/EP2009/060850. |
International Search Report, dated Feb. 24, 2010, in related International Application No. PCT/EP2009/060850. |
International Preliminary Report on Patentability and Written Opinion, dated Sep. 25, 2012, in corresponding International Application No. PCT/EP2011/054190. |
International Search Report, dated Jul. 7, 2011, in corresponding International Application No. PCT/EP2011/054190. |
Related U.S. Appl. No. 13/634,738, filed Nov. 5, 2011. |
Non-Final Office Action dated Sep. 19, 2013, in related U.S. Appl. No. 13/634,738. |
Final Office Action dated Mar. 6, 2014, in related U.S. Appl. No. 13/634,738. |
Related U.S. Appl. No. 12/205,177 (issued as U.S. Patent No. 8,592,040), filed Sep. 5, 2008. |
Non-Final Office Action mailed May 17, 2011, in related U.S. Appl. No. 12/205,177. |
Final Office Action mailed Nov. 2, 2011, in related U.S. Appl. No. 12/205,177. |
Non-Final Office Action mailed Jun. 28, 2012, in related U.S. Appl. No. 12/205,177. |
Final Office Action mailed Feb. 12, 2013, in related U.S. Appl. No. 12/205,177. |
Number | Date | Country | |
---|---|---|---|
20120220705 A1 | Aug 2012 | US |
Number | Date | Country | |
---|---|---|---|
61447398 | Feb 2011 | US |